Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Greenwich Lifesciences, Inc. (GLSI)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$16.35+2.70%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for GLSI yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Advance clinical trials for HER2 cancer immunotherapies | Greenwich LifeSciences is developing new cancer treatments for HER2 cancers. | Intact | Failure to meet clinical milestones or trial setbacks | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 13, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk, loss-making business rather than an established durable compounder. The long-term thesis is in a watch state, and confidence in the evidence is low.
The evidence snapshot provides no valuation or market-expectations data, so it is not possible to judge whether GLSI is cheap, fair, or expensive versus peers. It also does not show what the market already assumes about the company’s future.
Recent financial performance is neutral overall but below its industry cohort, and the snapshot says the company has missed across recent quarters. The next report carries near-term execution risk, while the improving Healthcare sector backdrop may offer support but does not establish stronger company fundamentals.
Over the next few quarters, the thesis hinges on whether financial performance improves and recent misses stop. A weakening jobs trend could add pressure to cyclical names, while continued strength or weakness in Healthcare bellwethers such as VRTX, REGN, and MRNA could reinforce or fade the sector tailwind.
For the 1-to-3-year view, GLSI remains a low-confidence, high-risk thesis with weak recent execution and a more favorable sector backdrop. The key question is whether company-level results improve enough to make that backdrop matter. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A primary condition in Greenwich Lifesciences, Inc.'s published investment case. The stated target is EPS loss narrows from -$1.48 in FY26 to less negative next year. |
| Broken |
| EPS loss worsens or stays below -$1.48 in FY26 |
Diluted EPS: $-0.27 per share FY2026-Q2; GAAP. Published target: EPS loss narrows from -$1.48 in FY26 to less negative next year. Annual target cannot be compared with a quarterly or TTM observation. Aug 11, 2026-0.27 USD/share · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Maintain Nasdaq compliance and avoid delisting | The company aims to stabilize its finances and regain Nasdaq compliance. | Under Pressure | Nasdaq delisting or failure to cure noncompliance within 1 year | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-1.17 → $-1.17 · observed estimates
$0.01B → $0.01B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-1.17 | $8,750,000 | 1 / 1 |
| 2026-07-25 | $-1.17 | $8,750,000 | 1 / 1 |
| 2026-07-26 | $-1.17 | $8,750,000 | 1 / 1 |
| 2026-07-27 | $-1.17 | $8,750,000 | 1 / 1 |
| 2026-07-28 | $-1.17 | $8,750,000 | 1 / 1 |
| 2026-07-29 | $-1.17 | $8,750,000 | 1 / 1 |
| 2026-07-30 | $-1.17 | $0 | 1 / 1 |
| 2026-07-31 | $-1.17 | $8,750,000 | 1 / 1 |
| 2026-08-01 | $-1.17 | $8,750,000 | 1 / 1 |
| 2026-08-02 | $-1.17 | $0 | 1 / 1 |
| 2026-08-03 | $-1.17 | $0 | 1 / 1 |
| 2026-08-04 | $-1.17 | $0 | 1 / 1 |
| 2026-08-05 | $-1.17 | $8,750,000 | 1 / 1 |
| 2026-08-06 | $-1.17 | $0 | 1 / 1 |
| 2026-08-07 | $-1.17 | $8,750,000 | 1 / 1 |
| 2026-08-08 | $-1.17 | $0 | 1 / 1 |
| 2026-08-09 | $-1.17 | $0 | 1 / 1 |
| 2026-08-10 | $-1.17 | $0 | 1 / 1 |
| 2026-08-12 | $-1.17 | $0 | 1 / 1 |
| 2026-08-13 | $-1.17 | $8,750,000 | 1 / 1 |
| 2026-08-14 | $-1.17 | $8,750,000 | 1 / 1 |
| 2026-08-15 | $-1.17 | $8,750,000 | 1 / 1 |
| 2026-08-16 | $-1.17 | $8,750,000 | 1 / 1 |
| 2026-08-17 | $-1.17 | $8,750,000 | 1 / 1 |
| 2026-08-18 | $-1.17 | $8,750,000 | 1 / 1 |
| 2026-08-19 | $-1.17 | $8,750,000 | 1 / 1 |
| 2026-08-20 | $-1.17 | $8,750,000 | 1 / 1 |
| 2026-08-21 | $-1.17 | $8,750,000 | 1 / 1 |
| 2026-08-22 | $-1.17 | $8,750,000 | 1 / 1 |
| 2026-08-23 | $-1.17 | $8,750,000 | 1 / 1 |
| 2026-08-24 | $-1.17 | $8,750,000 | 1 / 1 |
| 2026-08-25 | $-1.17 | $8,750,000 | 1 / 1 |
| 2026-08-26 | $-1.17 | $8,750,000 | 1 / 1 |
| 2026-08-27 | $-1.17 | $8,750,000 | 1 / 1 |
| 2026-08-28 | $-1.17 | $8,750,000 | 1 / 1 |
| 2026-08-29 | $-1.17 | $8,750,000 | 1 / 1 |
| 2026-08-30 | $-1.17 | $8,750,000 | 1 / 1 |
| 2026-08-31 | $-1.17 | $8,750,000 | 1 / 1 |
| 2026-09-01 | $-1.17 | $8,750,000 | 1 / 1 |
| 2026-09-02 | $-1.17 | $8,750,000 | 1 / 1 |
| 2026-09-03 | $-1.17 | $8,750,000 | 1 / 1 |
| 2026-09-04 | $-1.17 | $8,750,000 | 1 / 1 |
| 2026-09-05 | $-1.17 | $8,750,000 | 1 / 1 |
| 2026-09-06 | $-1.17 | $8,750,000 | 1 / 1 |
| 2026-09-07 | $-1.17 | $8,750,000 | 1 / 1 |
| 2026-09-08 | $-1.17 | $8,750,000 | 1 / 1 |
| 2026-09-09 | $-1.17 | $8,750,000 | 1 / 1 |
| 2026-09-10 | $-1.17 | $8,750,000 | 1 / 1 |
| 2026-09-11 | $-1.17 | $8,750,000 | 1 / 1 |
| 2026-09-12 | $-1.17 | $8,750,000 | 1 / 1 |
| 2026-09-13 | $-1.17 | $8,750,000 | 1 / 1 |
| 2026-09-14 | $-1.17 | $8,750,000 | 1 / 1 |
| 2026-09-15 | $-1.17 | $8,750,000 | 1 / 1 |
| 2026-09-16 | $-1.17 | $8,750,000 | 1 / 1 |
| 2026-09-17 | $-1.17 | $8,750,000 | 1 / 1 |
| 2026-09-18 | $-1.17 | $8,750,000 | 1 / 1 |
| 2026-09-19 | $-1.17 | $8,750,000 | 1 / 1 |
| 2026-09-20 | $-1.17 | $8,750,000 | 1 / 1 |
| 2026-09-21 | $-1.17 | $8,750,000 | 1 / 1 |
| 2026-09-22 | $-1.17 | $8,750,000 | 1 / 1 |
| 2026-09-23 | $-1.17 | $8,750,000 | 1 / 1 |
| 2026-09-24 | $-1.17 | $8,750,000 | 1 / 1 |
| 2026-09-25 | $-1.17 | $8,750,000 | 1 / 1 |
| 2026-09-26 | $-1.17 | $8,750,000 | 1 / 1 |
| 2026-09-27 | $-1.17 | $8,750,000 | 1 / 1 |
| 2026-09-28 | $-1.17 | $8,750,000 | 1 / 1 |
| 2026-09-29 | $-1.17 | $8,750,000 | 1 / 1 |
| 2026-09-30 | $-1.17 | $8,750,000 | 1 / 1 |
| 2026-10-01 | $-1.17 | $8,750,000 | 1 / 1 |
| 2026-10-02 | $-1.17 | $8,750,000 | 1 / 1 |
| 2026-10-03 | $-1.17 | $8,750,000 | 1 / 1 |
| 2026-10-04 | $-1.17 | $8,750,000 | 1 / 1 |
| 2026-10-05 | $-1.17 | $8,750,000 | 1 / 1 |
| 2026-10-06 | $-1.17 | $8,750,000 | 1 / 1 |
| 2026-10-07 | $-1.17 | $8,750,000 | 1 / 1 |
| 2026-10-08 | $-1.17 | $8,750,000 | 1 / 1 |
| 2026-10-09 | $-1.17 | $8,750,000 | 1 / 1 |
| 2026-10-10 | $-1.17 | $8,750,000 | 1 / 1 |
| 2026-10-11 | $-1.17 | $8,750,000 | 1 / 1 |
| 2026-10-12 | $-1.17 | $8,750,000 | 1 / 1 |
| 2026-10-13 | $-1.17 | $8,750,000 | 1 / 1 |
| 2026-10-14 | $-1.17 | $8,750,000 | 1 / 1 |
| 2026-10-15 | $-1.17 | $8,750,000 | 1 / 1 |
| 2026-10-16 | $-1.17 | $8,750,000 | 1 / 1 |
| 2026-10-17 | $-1.17 | $8,750,000 | 1 / 1 |
| 2026-10-18 | $-1.17 | $8,750,000 | 1 / 1 |
| 2026-10-19 | $-1.17 | $8,750,000 | 1 / 1 |
| 2026-10-20 | $-1.17 | $8,750,000 | 1 / 1 |
| 2026-10-21 | $-1.17 | $8,750,000 | 1 / 1 |
| 2026-10-22 | $-1.17 | $8,750,000 | 1 / 1 |
| 2026-10-23 | $-1.17 | $8,750,000 | 1 / 1 |
| 2026-10-24 | $-1.17 | $8,750,000 | 1 / 1 |
| 2026-10-25 | $-1.17 | $8,750,000 | 1 / 1 |
| 2026-10-26 | $-1.17 | $8,750,000 | 1 / 1 |
| 2026-10-27 | $-1.17 | $8,750,000 | 1 / 1 |
| 2026-10-28 | $-1.17 | $8,750,000 | 1 / 1 |
| 2026-10-29 | $-1.17 | $8,750,000 | 1 / 1 |
| 2026-10-30 | $-1.17 | $8,750,000 | 1 / 1 |
| 2026-10-31 | $-1.17 | $8,750,000 | 1 / 1 |
| 2026-11-01 | $-1.17 | $8,750,000 | 1 / 1 |
| 2026-11-02 | $-1.17 | $8,750,000 | 1 / 1 |
| 2026-11-03 | $-1.17 | $8,750,000 | 1 / 1 |
| 2026-11-04 | $-1.17 | $8,750,000 | 1 / 1 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 2 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.